Clinical Trial Update: Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches [Phase 2]

View source ↗

Summary

Phase 2 trial update for taselisib as therapy in patients with stage IV squamous cell lung cancer and matching biomarkers; trial completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Carcinoma

Drugs mentioned

• Taselisib (GDC-0032)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-03-06